The effect of a therapeutic dendritic cell-based cancer vaccination depends on the blockage of CTLA-4 signaling

Ö Met, M Wang, AE Pedersen, MH Nissen, S Buus… - Cancer letters, 2006 - Elsevier
Ö Met, M Wang, AE Pedersen, MH Nissen, S Buus, MH Claesson
Cancer letters, 2006Elsevier
Dendritic cells (DCs) were pulsed with the H-2Kb binding OVA257-264-peptide (SIINFEKL),
and used as one single-injection vaccine in combination with anti-CTLA-4 monoclonal
antibody (mAb) to treat mice inoculated 3 days previously with 3× 105 E. G7-OVA lymphoma
cells. Neither DC vaccination nor CTLA-4 blockage alone prevented tumor growth in tumor
challenged mice. In contrast, the combination of one vaccination and injection of anti-CTLA-
4 mAb lead to rejection or retarded tumor growth in more than 60% of the mice. The OVA …
Dendritic cells (DCs) were pulsed with the H-2Kb binding OVA257-264-peptide (SIINFEKL), and used as one single-injection vaccine in combination with anti-CTLA-4 monoclonal antibody (mAb) to treat mice inoculated 3 days previously with 3×105 E.G7-OVA lymphoma cells. Neither DC vaccination nor CTLA-4 blockage alone prevented tumor growth in tumor challenged mice. In contrast, the combination of one vaccination and injection of anti-CTLA-4 mAb lead to rejection or retarded tumor growth in more than 60% of the mice. The OVA-transgene or the SIINFEKL-epitope was not lost in the progressing tumors of vaccinated mice, however, the highest degree of anti-SIINFEKL reactivity of host CTLs in an IFN-γ ELISPOT assay was found only in mice showing complete tumor rejection. Vaccinated mice having rejected E.G7-OVA tumors were capable of rejecting subsequent challenges with 1×106 E.G7-OVA tumor cells, and later on these mice even rejected wild-type EL-4 tumor cells indicating that tumor epitope spreading takes place during the process of vaccination-induced E.G7-OVA rejection. In agreement with these observations, mice having rejected E.G7-OVA tumors showed long lasting CTL memory in spleen and bone marrow towards both the SIINFEKL-peptide and other EL-4-derived tumor rejecting epitopes.
Elsevier